Catalyst Pharmaceuticals (CPRX) Total Liabilities (2010 - 2026)

Catalyst Pharmaceuticals' Total Liabilities history runs 17 years deep, the most recent figure standing at $134.9 million for Q1 2026.

• Quarterly Total Liabilities rose 17.74% year-over-year to $134.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.9 million (up 17.74% YoY) and the FY2025 annual result came in at $149.7 million, up 20.95% from the prior year.
• Total Liabilities was $134.9 million for Q1 2026 at Catalyst Pharmaceuticals, down from $149.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $149.7 million in Q4 2025 and bottomed at $26.2 million in Q2 2022.
• A 5-year average of $90.9 million and a median of $85.3 million in 2024 frame the typical range for Total Liabilities.
• Peak annual rise in Total Liabilities reached 175.0% in 2023, while the deepest fall reached 2.52% in 2023.
• Catalyst Pharmaceuticals' Total Liabilities stood at $75.2 million in 2022, then advanced by 9.34% to $82.2 million in 2023, then soared by 50.52% to $123.8 million in 2024, then gained by 20.95% to $149.7 million in 2025, then declined by 9.88% to $134.9 million in 2026.
• Business Quant data shows CPRX's Total Liabilities at $134.9 million in Q1 2026, $149.7 million in Q4 2025, and $131.4 million in Q3 2025.